Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Tuesday, Oct 24, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x